Mark B. Meads
Impact in
- Hematology top 2%
- Multiple Myeloma Research and Treatments
- Oncology top 5%
- Cancer Cells and Metastasis
- Chemokine receptors and signaling
Papers in
- Hematology 23
- Multiple Myeloma Research and Treatments 21
- Oncology 19
- Cancer Treatment and Pharmacology 5
- Peptidase Inhibition and Analysis 3
- Co-authors
- William S. DaltonRobert A. GatenbyLori HazlehurstKenneth H. ShainPeter G. MedveczkyRichard JoveMei HuangDanielle N. Yarde
- Journals
- Blood (16 papers)Journal of Visualized Experiments (2 papers)Nature reviews. Cancer (1 paper)British Journal of Haematology (1 paper)Clinical Cancer Research (1 paper)
- Partner nations
- United StatesGermanyCanada
In The Last Decade
Mark B. Meads
32 papers receiving 1.6k citations
Hit Papers
Peers
Comparison fields: 5 of 81
- Hematology 441
- Oncology 753
- Cancer Research 307
- Immunology and Allergy 103
- Immunology 307
Countries citing papers authored by Mark B. Meads
This map shows the geographic impact of Mark B. Meads's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark B. Meads with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark B. Meads more than expected).
Fields of papers citing papers by Mark B. Meads
This network shows the impact of papers produced by Mark B. Meads. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark B. Meads. The network helps show where Mark B. Meads may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mark B. Meads, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 0 | |
| 4 | 2023 | 3 | |
| 5 | 2023 | 1 | |
| 6 | 2021 | 10 | |
| 7 | 2020 | 1 | |
| 8 | 2020 | 16 | |
| 9 | 2019 | 7 | |
| 10 | 2017 | 1 | |
| 11 | 2016 | 64 | |
| 12 | 2016 | 4 | |
| 13 | 2015 | 13 | |
| 14 | 2015 | 33 | |
| 15 | 2015 | 1 | |
| 16 | 2013 | 1 | |
| 17 | 2009 | 23 | |
| 18 | Environment-mediated drug resistance: a major contributor to minimal residual disease Hit paper breakdown → | 2009 | 679 |
| 19 | 2008 | 5 | |
| 20 | 2004 | 54 |
About Mark B. Meads
Mark B. Meads is a scholar working on Hematology, Oncology, Immunology and Allergy, Molecular Biology and Cancer Research, having authored 36 papers that have together received 1.6k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (21 papers), Protein Degradation and Inhibitors (13 papers), Histone Deacetylase Inhibitors Research (6 papers), Cancer Treatment and Pharmacology (5 papers), Ubiquitin and proteasome pathways (5 papers), Cancer therapeutics and mechanisms (4 papers), Peptidase Inhibition and Analysis (3 papers) and Cell Adhesion Molecules Research (3 papers). The work is most often cited by research in Hematology (441 citations), Oncology (753 citations), Cancer Research (307 citations), Immunology and Allergy (103 citations) and Immunology (307 citations). Mark B. Meads has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include William S. Dalton, Robert A. Gatenby, Lori Hazlehurst, William S. Dalton, Kenneth H. Shain, Peter G. Medveczky, Richard Jove, Mei Huang, Danielle N. Yarde and Jana L. Dawson. Their work appears in journals such as Blood, Journal of Visualized Experiments, Nature reviews. Cancer, British Journal of Haematology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.